Disease · MONDO_0006036

granulosa cell tumor

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. granulosa cell tumor. Diseases, record MONDO_0006036. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006036

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: granulosa cell tumor; Open Targets
Open Targets ID: MONDO_0006036; Open Targets
Other names: granulosa cell neoplasm, granulosa cell neoplasm (disease), granulosa cell tumor, adult type, granulosa cell tumor, adult type (morphologic abnormality), granulosa cell tumor, sarcomatoid, granulosa cell tumour, sarcomatoid, neoplasm of granulosa cell, tumor of granulosa cell, tumour of granulosa cell; Open Targets
Disease Ontology: DOID:2999; Disease Ontology
MeSH: D006106; MeSH
NCI Thesaurus: C3070; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 6 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ABEMACICLIB	CHEMBL3301610	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ANASTROZOLE	CHEMBL1399	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ONAPRISTONE	CHEMBL1908373	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets6

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CYP19A1	Aromatase	2	Cytochrome P450 19A1 inhibitor	Phase 2	https://conductscience.org/library/genes/1588	Drugs and targets
CDK4	Cyclin-dependent kinase 4	1	Cyclin-dependent kinase 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1019	Drugs and targets
CDK6	Cyclin-dependent kinase 6	1	Cyclin-dependent kinase 6 inhibitor	Phase 2	https://conductscience.org/library/genes/1021	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
PDCD1	Programmed cell death protein 1	1	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PGR	Progesterone receptor	1	Progesterone receptor antagonist	Phase 2	https://conductscience.org/library/genes/5241	Drugs and targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03909152	A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone	Phase 2	34	2025-07-28	Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer	ANASTROZOLE, ONAPRISTONE	Its record names the disease	ClinicalTrials.gov
NCT02923934	A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers	Phase 2	120		Gastrointestinal Cancer, Neuroendocrine Tumours, Malignant Female Reproductive System Neoplasm	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT05872204	Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer	Phase 2	100		Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor	ABEMACICLIB, LETROZOLE	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38453176	DERIVED	1	PubMed
32729929	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006036

GET https://conductscience.org/api/diseases/v1/MONDO_0006036/drugs

API reference For AI assistants